Clinical response to linaclotide at week 4 predicts sustained response in irritable bowel syndrome with constipation and improvements in digestive and extra-digestive symptoms

BACKGROUND: Linaclotide is approved for the treatment of moderate-to-severe irritable bowel syndrome (IBS) with constipation (IBS-C) in adults. This study aimed to assess factors predictive of a clinical response and improvements in non-IBS symptoms with linaclotide treatment in a Spanish patient po...

Descripción completa

Detalles Bibliográficos
Autores principales: Serrano-Falcón, Blanca, Delgado-Aros, Sílvia, Mearin, Fermín, Ciriza de los Ríos, Constanza, Serra, Jordi, Mínguez, Miguel, Montoro Huguet, Miguel, Perelló, Antonia, Santander, Cecilio, Pérez Aisa, Ángeles, Bañón-Rodríguez, Inmaculada, Rey, Enrique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683318/
https://www.ncbi.nlm.nih.gov/pubmed/31428193
http://dx.doi.org/10.1177/1756284819857358

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683318/
https://www.ncbi.nlm.nih.gov/pubmed/31428193
http://dx.doi.org/10.1177/1756284819857358

Ejemplares similares